Non-Muscle Invasive (NMIBC)

IL-15 Receptor Lymphocyte–Stimulating Agent NAI + BCG in BCG-Unresponsive Papillary-Only NMIBC

ANKTIVA® Plus BCG Demonstrates Durable Response, Bladder Preservation, and 96% Survival in BCG-Unresponsive Papillary NMIBC

This article reviews long-term outcomes of the IL-15 receptor agonist nogapendekin alfa inbakicept (NAI) combined with intravesical bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive, high-grade...

Latest Post

Prospective DRIVE Study Demonstrates Strong Diagnostic Performance of CxBladder Triage Plus in Hematuria Evaluation

The CxBladder Triage Plus DRIVE study showed high accuracy in detecting urothelial carcinoma in patients...

New CMS J-Code Set to Enhance Adoption of Mitomycin Therapy for Recurrent LG-IR-NMIBC

CMS has assigned a permanent J-code (J9282) to ZUSDURI, an intravesical mitomycin therapy for recurrent...

Sasanlimab-BCG Combination Achieves 32% Risk Reduction in BCG-Naïve High-Risk NMIBC: Phase 3 CREST Trial Results

32% risk reduction in high-risk bladder cancer with sasanlimab-BCG combo—first treatment advance in 30+ years...

FDA Approves Gemcitabine Intravesical System (Inlexzo) for BCG-Unresponsive Bladder Cancer

FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in...

TAR-200 Achieves 82% Complete Response in BCG-Refractory Bladder Cancer: SunRISe-1 Results

New drug-releasing system, TAR-200, eliminated tumors in 82% of patients in phase 2 clinical trial...

Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-Grade Non–Muscle-Invasive Bladder Cancer

XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection...

Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy

Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal...

FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12...

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

CR rates greater than 80% achieved with TAR-200 device - first time we've seen rates...

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV while reducing cystoscopy burden by...

Urothelial Carcinoma Insight Center

Muscle Invasive (MIBC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest